Ceftaroline fosamil + Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam + Cephalexin or Clindamycin or Linezolid
Phase 2/3Completed 1 views this week 0 watching💤 Quiet
Interest: 38/100
38
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Infections, Pediatrics
Conditions
Infections, Pediatrics
Trial Timeline
Dec 1, 2011 → Jul 1, 2014
NCT ID
NCT01400867About Ceftaroline fosamil + Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam + Cephalexin or Clindamycin or Linezolid
Ceftaroline fosamil + Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam + Cephalexin or Clindamycin or Linezolid is a phase 2/3 stage product being developed by AstraZeneca for Infections, Pediatrics. The current trial status is completed. This product is registered under clinical trial identifier NCT01400867. Target conditions include Infections, Pediatrics.
What happened to similar drugs?
20 of 20 similar drugs in Infections, Pediatrics were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
15
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01400867 | Phase 2/3 | Completed |
Competing Products
20 competing products in Infections, Pediatrics